YaFarm Technologies Announces ISCI Clinical Study
February 25 2013 - 6:35AM
Marketwired
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the
Company) announced today that the Integrative Stem Cell Institute
(ISCI), a premier provider of point-of-care, stem cell-based
therapies, has initiated its first clinical study in Degenerative
Neuromuscular Diseases (DNMD).
The clinical studies will be conducted at the ISCI facility in
the Hospital Galenia in Cancun, Mexico and will consist of an
integrative approach that will combine autologous, adult progenitor
(stem) cells with physical therapy, nutrition and other
complementary treatments to multiple sclerosis (MS), Alzheimer's
and Parkinson's disease. Patients will spend up to three weeks in
Cancun for the therapies. The patient's own cells will be processed
in the ISCI's state-of-the-art laboratory with a class 10,000, ISO
7 clean room. As part of the study protocol all patients will have
to meet a strict set of inclusion and exclusion criteria and be
evaluated by a 3rd party physician prior to treatment who will also
serve to provide long-term and independent collection of outcome
data, and the reporting of any adverse event or complication
stemming from the treatment.
"Today there are literally hundreds of thousands of people
living with DNMD," says David Audley, CEO of the ISCI. "Estimates
from the National Institutes of Health provide a grim reminder to
what many already know: these diseases touch many people." The
National Institutes for Neurological Disorders and Stroke (NINDS)
estimates that there are currently 250,000 people in the US alone
with MS(1), while the University of Kansas Institute for
Neurological Discoveries believes that Parkinson's disease affects
nearly 1.5 million(2) and the National Institutes for Aging
estimates that over 5 million Americans may suffer from
Alzheimer's.(3) "And while conventional medicine may provide relief
for many," continues Mr Audley, "Thousands of others find
themselves suffering with limited or no options for treatment. It
is for these patients that we have initiated these studies."
About The Integrative Stem Cell Institute
(ISCI) The Integrative Stem Cell Institute (ISCI) is a premier
provider of point-of-care, stem cell-based therapies for patients
from around the world. With a state of the art laboratory housed
within the Hospital Galenia in Cancun, Mexico, the ISCI combines
the most advanced scientific application of stem cells with second
to none medical care within the structure of adaptive clinical
trials to effectively track long term outcomes and assure patient
safety. More information on the Integrative Stem Cell Institute is
available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, adequate financing, and
other material risks. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance, or achievements to be materially
different from the statements made herein.
(1) NINDS:
http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm
(2) Univ of Kansas:
http://www.indkc.org/neuromuscular_and_movement.html
(3) NIA:
http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet
Contact: The Integrative Stem Cell Institute Contact: Miranda
Abrahams Miranda@iscelli.com Investor Contact Atlanta Capital
Partners, LLC David Kugelman (866) 692-6847 info@atlcp.com
Profile Solutions (CE) (USOTC:PSIQ)
Historical Stock Chart
From May 2024 to Jun 2024
Profile Solutions (CE) (USOTC:PSIQ)
Historical Stock Chart
From Jun 2023 to Jun 2024